Amarin Corp. PLC ADR (AMRN): Price and Financial Metrics

Amarin Corp. PLC ADR (AMRN): $1.22

0.03 (+2.52%)

POWR Rating

Component Grades













Add AMRN to Watchlist
Sign Up

Industry: Biotech



in industry


  • Value is the dimension where AMRN ranks best; there it ranks ahead of 86.08% of US stocks.
  • The strongest trend for AMRN is in Momentum, which has been heading up over the past 179 days.
  • AMRN's current lowest rank is in the Growth metric (where it is better than 9.69% of US stocks).

AMRN Stock Summary

  • AMRN's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.34 -- higher than only 3.67% of US-listed equities with positive expected earnings growth.
  • In terms of twelve month growth in earnings before interest and taxes, AMARIN CORP PLC is reporting a growth rate of -1,426.86%; that's higher than only 1.02% of US stocks.
  • As for revenue growth, note that AMRN's revenue has grown -30.12% over the past 12 months; that beats the revenue growth of just 6.35% of US companies in our set.
  • Stocks with similar financial metrics, market capitalization, and price volatility to AMARIN CORP PLC are NEO, EVER, CLIR, CDXC, and PMD.
  • AMRN's SEC filings can be seen here. And to visit AMARIN CORP PLC's official web site, go to

AMRN Valuation Summary

  • In comparison to the median Healthcare stock, AMRN's EV/EBIT ratio is 133.72% lower, now standing at -2.9.
  • Over the past 145 months, AMRN's EV/EBIT ratio has gone up 1.1.

Below are key valuation metrics over time for AMRN.

Stock Date P/S P/B P/E EV/EBIT
AMRN 2022-11-25 1.1 0.8 -5.1 -2.9
AMRN 2022-11-23 1.1 0.8 -5.1 -2.9
AMRN 2022-11-22 1.1 0.8 -5.3 -3.1
AMRN 2022-11-21 1.1 0.8 -5.0 -2.8
AMRN 2022-11-18 1.1 0.8 -5.2 -3.0
AMRN 2022-11-17 1.1 0.8 -5.1 -2.9

AMRN Growth Metrics

    Its 3 year price growth rate is now at -91.1%.
  • Its 5 year cash and equivalents growth rate is now at 236.83%.
  • Its 3 year net income to common stockholders growth rate is now at 80.98%.
Over the past 52 months, AMRN's revenue has gone up $225,651,000.

The table below shows AMRN's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2022-09-30 423.439 -209.884 -91.961
2022-06-30 475.599 -196.211 -99.972
2022-03-31 535.647 -146.68 -22.208
2021-12-31 583.187 -66.537 7.729
2021-09-30 605.947 -76.62 -2.043
2021-06-30 620.408 -61.227 4.32

AMRN's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • AMRN has a Quality Grade of B, ranking ahead of 81.41% of graded US stocks.
  • AMRN's asset turnover comes in at 0.626 -- ranking 51st of 680 Pharmaceutical Products stocks.
  • CEMI, NEOG, and INSM are the stocks whose asset turnover ratios are most correlated with AMRN.

The table below shows AMRN's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.626 0.793 0.031
2021-03-31 0.628 0.792 0.019
2020-12-31 0.652 0.786 -0.036
2020-09-30 0.641 0.784 -0.042
2020-06-30 0.608 0.781 -0.052
2020-03-31 0.668 0.778 -0.163

AMRN Stock Price Chart Interactive Chart >

Price chart for AMRN

AMRN Price/Volume Stats

Current price $1.22 52-week high $3.82
Prev. close $1.19 52-week low $1.04
Day low $1.16 Volume 1,146,600
Day high $1.23 Avg. volume 3,651,710
50-day MA $1.19 Dividend yield N/A
200-day MA $1.83 Market Cap 492.67M

Amarin Corp. PLC ADR (AMRN) Company Bio

Amarin Corporation plc, a biopharmaceutical company, focuses on developing and commercializing therapeutics for the treatment of cardiovascular diseases in the United States. The company was founded in 1989 and is based in Dublin, Ireland.

AMRN Latest News Stream

Event/Time News Detail
Loading, please wait...

AMRN Latest Social Stream

Loading social stream, please wait...

View Full AMRN Social Stream

Latest AMRN News From Around the Web

Below are the latest news stories about AMARIN CORP PLC that investors may wish to consider to help them evaluate AMRN as an investment opportunity.

Why Amarin (AMRN) Stock Might be a Great Pick

Amarin (AMRN) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

Yahoo | November 21, 2022

Why Amarin Stock Was a Winner Today

Before market open, Amarin announced that its Vazkepa (brand-named Vascepa in the U.S.) has been approved by Australia's Therapeutic Good Administration (TGA). Amarin didn't hesitate to mention that the Australian nod represents the fifth regulatory approval for Vazkepa/Vascepa. Among these jurisdictions are the U.S. and the European Union, which consists of 27 countries on that continent.

Yahoo | November 15, 2022

Amarin Announces VAZKEPA® (icosapent ethyl) Approved by the Therapeutic Goods Administration (TGA) in Australia

-- VAZKEPA® Approved in Australia to Reduce the Risk of CV Events in Adult Statin-Treated Patients with High CV Risk with Elevated Triglycerides -- -- Marks Fifth Regulatory Approval for VASCEPA®/VAZKEPA® Franchise in Key International Markets in 2022 -- DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 15, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Australia’s Therapeutic Good Administration (TGA) has granted approval to VAZKEPA (icosapent ethyl). The TGA appro

Yahoo | November 15, 2022

Amarin to Present at Jefferies London Healthcare Conference

DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that Karim Mikhail, Amarin’s president and chief executive officer, is scheduled to participate at the Jefferies London Healthcare Conference. Jefferies London Healthcare Conference (November 15-17th, 2022; London) Date/Time:November 16, 2022, 9:40 a.m. ET/ 2:40 p.m. GMT+1 Webcast: The presentation will be webcast live and archi

Yahoo | November 9, 2022

Amarin Highlights Key Data Presented at American Heart Association 2022 Scientific Sessions for VASCEPA®/VAZKEPA (icosapent ethyl) and Patient Care

-- Independent RESPECT-EPA Study Now Third in a Series of Trials to Underscore CV Risk Reduction Benefits of Eicosapentaenoic Acid for Patients -- -- PROMINENT Study Failed to Show CV Risk Reduction Benefit of the Fibrate Class for Statin-Treated High-Risk Patients -- DUBLIN, Ireland and BRIDGEWATER, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today highlighted key data presented at the American Heart Association (AHA) 2022 Scientific Sessions relevant to VASCEPA

Yahoo | November 7, 2022

Read More 'AMRN' Stories Here

AMRN Price Returns

1-mo 4.27%
3-mo 0.83%
6-mo -25.61%
1-year -65.83%
3-year -94.64%
5-year -60.90%
YTD -63.80%
2021 -31.08%
2020 -77.19%
2019 57.53%
2018 239.40%
2017 30.19%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.802 seconds.